

FOR IMMEDIATE RELEASE

CONTACT:

Eric Button
BioMarker Group
(704) 707-3759
ebutton@biomarkergroup.com

Quest Diagnostics Offers New GlycoMark 1,5-AG Diabetes Blood Test to Complement Hemoglobin A1c Testing in Patients with Diabetes

Kannapolis, North Carolina, June 22 , 2007 – GlycoMark today announced at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, that it has entered into an agreement with Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information, and services, to offer a new blood test to enable physicians to monitor intermediate glycemic control in people with diabetes by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG).

“This new blood test for diabetes has the potential to become an integral part of diabetes test offerings, providing complementary information to hemoglobin A1c (HbA1c), a key indicator for diabetes control, by providing a more specific measure of after-meal glucose levels and short-term glycemic control,” said John Buse, M.D. , Ph.D., a professor of medicine and chief of the Division of Endocrinology at the University of North Carolina School of Medicine at Chapel Hill.

In a recent study completed by Kathleen Dungan, M.D. and John Buse, M.D., Ph.D. at the University of North Carolina and Steve Wittlin, M.D. at the University of Rochester and published in the American Diabetes Association *Diabetes Care* journal demonstrates that the GlycoMark 1,5-AG test is a better measure of after-meal glucose levels compared to standard tests for diabetes. This is important as a growing body of evidence suggests that controlling after-meal glucose levels play a significant role in achieving optimal glycemic control and reducing the burden of cardiovascular complications, the leading cause of death in patients with diabetes.

In recent clinical studies using new agents to target after-meal glucose levels, 1,5-AG was reported to respond more sensitively to changes in after-meal glucose levels than hemoglobin A1c (see associated [press release](#)). These are important findings as 1,5-AG revealed underlying treatment effects of after-meal glucose control which were not readily apparent by HbA1c measurements – giving physicians the ability to make necessary adjustments to these medications.

Additional information on the GlycoMark blood test is available at www.glycomark.com.

About Quest Diagnostics

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers

the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: <http://www.questdiagnostics.com>